Summit Therapeutics Inc. (SMMT)
Summit Therapeutics is developing ivonescimab, an investigational cancer antibody being tested in lung and colorectal cancer. It last closed at $10.67 on Nov 17, down 9.73% on the day. SMMT last reported earnings on Thu, Jul 23, 2026. The average 12-month price target from 5 analysts is $25.98 (+143.5% from the last close), with a high of $42.00 and a low of $11.90. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From SMMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on SMMT in the past 90 days. The average target is $25.98, with a high of $42.00 and a low of $11.90, compared with the last close of $10.67.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Citigroup | Target lowered | Buy | $43 → $42 |
| Nov 16 | Barclays | Target lowered | Hold | $20 → $18 |
| Nov 16 | Evercore ISI Group | Maintained | Buy | $33 |
| Oct 1 | Barclays | Maintained | Hold | $20 |
| Sep 29 | Citigroup | Maintained | Buy | $43 |
Technical Analysis
The stock is 43% below its 20 day and 51% below its 50 day average. It is 51% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), oversold. The nearest support is the 52 week low at $10.53, and the nearest resistance the Pivot at $11.04.
| RSI (14) | 31.98 | Weak, oversold below 30 | Neutral |
| MACD | -0.73 | Below its signal line | Bearish |
| Stochastic | 2.8 | Near the bottom of its range | Oversold |
| ADX (14) | 18.6 | No clear trend | |
| Williams %R | -98.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -290.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −32.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.34 | Typical daily range, 12.6% of price |
| RSI (14) | 36.66 | Weak, oversold below 30 | Neutral |
| MACD | -0.58 | Below its signal line | Bearish |
| Stochastic | 30.6 | Middle of its range | Neutral |
| ADX (14) | 10.6 | No clear trend | |
| Williams %R | -98.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -175.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −39.2% | Change over 10 sessions | Bearish |
| ATR (14) | $2.64 | Typical daily range, 24.8% of price |
What happened before
See how SMMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SMMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in SMMT in the last 90 days.
SMMT Institutional Ownership
Full report →- ▲198 buying vs 107 selling
- ●Held by funds -0.2 pts
- ▲Funds holding +49
- ▼Superinvestors: 1 added, 2 cut
- ▼Put/call 0.67 to 0.92
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 295 | 246 | +19.9% |
| In funds' top 10 | 1 | 1 | 0.0% |
| Held by funds | 16.9% | 17.0% | −0.2 pts |
| New / increased | 91 / 107 | 57 / 98 | +27.7% |
| Reduced / sold out | 66 / 41 | 57 / 35 | +16.3% |
| Put/call ratio | 0.92 | 0.67 | +37.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SMMT is in one of them and how their past SMMT trades turned out.
SMMT News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SMMT in an article yet. Here's the latest on the wider market.
About Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company based in Miami, Florida, that develops cancer medicines. Its lead candidate, ivonescimab, is an investigational antibody designed to act on two proteins, one that helps tumors evade the immune system and one that supports blood vessel growth in tumors. The company is testing ivonescimab in lung cancer and colorectal cancer, and it holds development and commercial rights in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Its intended users are cancer patients and the physicians who treat them.
- Headquarters
- Miami, FL


